NCT06367322View on ClinicalTrials.gov

Statins and Post-ERCP Acute Pancreatitis (Stark Project)

CompletedOBSERVATIONAL
Enrollment

1,016

Participants

Timeline

Start Date

January 10, 2017

Primary Completion Date

July 31, 2018

Study Completion Date

September 30, 2018

Conditions
Post-ERCP Acute Pancreatitis
Interventions
DRUG

Statin

"The primary objective of this study was to determine whether the use of statin has a protective effect against PEAP.~Patients undergoing ERCP for a specific medical indication were prospectively reviewed and the incidence of PEAP was compared according to whether or not the patients were receiving statin therapy."

Trial Locations (2)

03010

Alicante, Alicante

Hospital General Universitario de Alicante, Alicante

All Listed Sponsors
collaborator

European Pancreatic Club (EPC), Pancreas 2000 Educational Program

UNKNOWN

lead

Hospital General Universitario de Alicante

OTHER

NCT06367322 - Statins and Post-ERCP Acute Pancreatitis (Stark Project) | Biotech Hunter | Biotech Hunter